Tokenless

Computational biology

Mark Zuckerberg & Priscilla Chan: How AI Will Cure All Disease

Mark Zuckerberg & Priscilla Chan: How AI Will Cure All Disease

Priscilla Chan and Mark Zuckerberg of the Chan Zuckerberg Initiative (CZI) discuss their strategy to accelerate scientific discovery through the Biohub, an operating philanthropy at the intersection of frontier AI and biology. They detail the development of foundational tools like the Cell Atlas, a 'periodic table for biology,' and their new focus on building virtual cell models to allow scientists to test high-risk hypotheses in silico, ultimately aiming to cure, prevent, and manage all diseases.

Faster Science, Better Drugs

Faster Science, Better Drugs

Erik Torenberg, Patrick Hsu (Arc Institute), and Jorge Conde (a16z) discuss Arc's moonshot to create 'virtual cells' using foundation models to simulate biology. They cover why science is slow, how AI can accelerate drug discovery by predicting cellular perturbations, and the remaining bottlenecks in clinical trials and capital intensity that the biotech industry faces.

AI is Revolutionizing Scientific Discovery Featuring Nobel Laureate John Jumper

AI is Revolutionizing Scientific Discovery Featuring Nobel Laureate John Jumper

John Jumper, one of the creators of AlphaFold, discusses the journey of developing an AI system to solve the protein folding problem. He emphasizes that the breakthrough was driven more by novel research and a combination of "mid-scale ideas" than by raw data or compute scale alone. The talk covers the importance of blind-assessment benchmarks like CASP, the strategy of releasing a massive, accessible database to drive adoption and trust, and the unexpected ways the scientific community used the tool. He concludes by framing AI for science as a powerful amplifier for experimentalists, accelerating discovery by generating high-quality, testable hypotheses.

No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

Chai Discovery's co-founders discuss Chai 2, their new generative AI platform for antibody design. It achieves a nearly 20% hit rate from just 20 computational attempts, a 100-fold improvement over previous methods, signaling a shift from drug discovery to drug engineering.

A quest for a cure: AI drug design with Isomorphic Labs

A quest for a cure: AI drug design with Isomorphic Labs

Experts from Isomorphic Labs discuss how AI, particularly models like AlphaFold3, is revolutionizing drug discovery. They explain the shift from the slow, iterative process of traditional methods to a new era where generative AI can design novel molecules, optimize for multiple biological properties simultaneously, and pave the way for personalized medicine.